Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients
Recruiting · NCT07427537 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Clermont-Ferrand
View the official record on ClinicalTrials.gov →Interventions studied
Assessment of blood concentrations of microRNAsAssessment of blood concentrations of neurofilament light chainChemotherapy-induced peripheral neuropathy (CIPN) - gradeChemotherapy-induced peripheral neuropathy (CIPN) - severityNeuropathic pain assessmentPain assessement
What this trial is about
This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or
- Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.
Exclusion criteria
- Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),
- History of stroke,
- Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100),
- Pain (NRS ≥ 4/10),
- Pregnant or breastfeeding women,
- Patients under guardianship, curatorship, deprived of liberty, or under legal protection
Where it is running
2 locations listed.
- CHU Clermont-Ferrand - Clermont-Ferrand, France
- CHU Clermont-Ferrand - Clermont-Ferrand, France